NuCana Stock: Potential Turnaround In 2024 But Risky (NASDAQ:NCNA)

vdvornyk/iStock via Getty Images Thesis overview NuCana (NASDAQ:NCNA) is a UK-based biotech developing nucleotide molecules for various oncology indications. Its platform, called ProTide, has major advantages over traditional nucleoside analogues currently used as part of chemotherapy regimens. NCNA’s lead candidate is NUC-3373 (ProTide 5-fluorouracil). NCNA aims to replace traditional 5-fluoroucil (5FU) which is still being…

Read More